查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球癌症诊断市场人工智慧
市场调查报告书
商品编码
1351021

2023-2030 年全球癌症诊断市场人工智慧

Global Artificial Intelligence in Cancer Diagnostics Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

预计在预测期内（2023-2030年），全球癌症诊断市场人工智慧将以32.5%的复合年增长率成长。癌症诊断中的人工智慧（AI）是一种用于早期癌症诊断的自动化软体，透过在早期癌症检测的帮助下，可以为患者提供适当的治疗，从而降低死亡率。一些政府增加了医疗保健资讯科技 (IT) 支出，从而改善了全球的医疗保健基础设施。例如，美国联邦政府的医疗保健 IT 支出从 2020 年的 1,195 亿美元增加到 2021 年的 1,765 亿美元。政府为增加癌症诊断中人工智慧辅助技术的采用而采取的更多倡议预计将推动市场成长。

细分市场前景

全球癌症诊断市场中的人工智慧按应用、类型和最终用户进行细分。根据应用，市场分为筛检和诊断、肿瘤识别和监测。根据类型，市场细分为乳腺癌、前列腺癌、肺癌、大肠癌以及子宫颈癌、血癌和骨癌等其他癌症。此外，根据最终用户，市场细分为医院、诊断中心、研究机构、医疗机构和学术机构。在最终用户中，由于政府在医疗保健领域的倡议和资金不断增加，因此诊断中心细分市场预计将占据相当大的市场份额。

预计乳癌细分市场将在全球癌症诊断市场人工智慧中占据相当大的份额

其中，乳癌细分市场预计将占据相当大的市场份额。这种增长归因于全球乳癌病例的不断增加。据世界卫生组织 (WHO) 称，预计 2021 年将有超过 230 万新发乳癌病例和 685,000 例乳癌死亡病例。此外，大约一半的乳癌发生在没有特定危险因子的女性身上。因此，利用人工智慧和机器学习等先进技术在早期阶段检测乳癌，进一步促进产业成长。透过在早期发现癌症，可以为患者提供适当的治疗，从而降低死亡率。

区域展望

全球癌症诊断市场人工智慧根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于全球癌症病例数量不断增加，预计北美将在全球市场中占据显着份额。根据加拿大癌症统计数据，加拿大 43% 的女性和 45% 的男性一生中会罹患癌症。儘管如此，为了解决这个问题，该国正在整个医疗保健产业积极采用人工智慧。

亚太地区癌症诊断市场的全球人工智慧预计将以显着的复合年增长率成长

预计亚太地区在预测期内将以可观的复合年增长率成长。区域成长归因于人工智慧和机器学习在健康领域的日益普及，该地区的几项政府措施导致政府和私人组织的投资增加。该地区癌症病例的增加也是医疗保健领域采用人工智慧进行早期诊断的驱动因素。根据印度医学研究委员会国家癌症登记计划 (ICMR-NCRP)，政府向议会通报，该国癌症病例数量预计将从 2022 年的 1,770 万美元增加到 2025 年的 1,900 万美元。例如，NITI印度政府的公共政策智库Aayog 旨在与生物技术部合作建立一个成像生物库，其中将创建一个包含20,000 多名患者资料的癌症相关病理和放射学图像的资料库。

因此，该国正在大力转向在癌症诊断市场解决方案中采用人工智慧。例如，根据 NCBI 2022 年 4 月的一篇文章，人工智慧辅助大肠镜检查将腺瘤检出率提高到 29%，而传统大肠镜检查的检出率约为 20%。这点很重要，因为腺瘤检出率每增加 1%，大肠癌盛行率就会降低 3%。人工智慧允许整合基因组学、电子病历、放射影像、病理学和社交网路等各种流来预测临床决策，这有望改善患者的治疗结果。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • IBM Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Microsoft Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Pfizer Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 全球人工智慧在癌症诊断市场的应用
    • 筛检与诊断
    • 肿瘤识别
    • 监视
  • 按类型分類的全球癌症诊断市场人工智慧
    • 乳癌
    • 摄护腺癌
    • 肺癌
    • 大肠直肠癌
    • 其他（子宫颈癌、血癌、骨癌等）
  • 全球人工智慧在癌症诊断市场的最终用户
    • 医院
    • 诊断中心
    • 研究机构
    • 医学研究所和学者

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Therapixel
  • Sophia Genetics SA
  • Freenome Holdings, Inc.
  • Tempus Labs, Inc.
  • Janssen Pharmaceuticals
  • Path AI Inc.
  • DeepMind Technologies Ltd.
  • Cerner Corp.
  • RaySearch Laboratories
  • Flatiron health
  • Whiterabbit.ai
  • Oncology Analytics Inc.
  • Oncora Medical
  • Ibex Medical Analytics Ltd.
  • 4basecare Onco Solutions Pvt. Ltd .
Product Code: OMR2027621

Title: Global Artificial Intelligence in Cancer Diagnostics Market Size, Share & Trends Analysis Report by Application (Screening & Diagnosis, Tumor Identification and Surveillance), by type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Others (Cervical Cancer, blood cancer, bone cancer and other)), and by End User (Hospitals, Diagnostic centers, Research Organization, Medical Institute and academics),Forecast Period (2023-2030).

The global artificial intelligence in cancer diagnostics market is anticipated to grow at a CAGR of 32.5% during the forecast period (2023-2030). Artificial Intelligence (AI) in cancer diagnostics is an automated software used for early cancer diagnostics with the help of cancer detection at early stages, proper treatment can be provided to the patients, resulting in low death rates. Several governments have increased their healthcare Information Technology (IT) expenditure, which in turn to improve healthcare infrastructure around the globe. For instance, the healthcare IT spending of the US federal government increased from $119.5 billion in 2020 to $176.5 billion in 2021. Increasing initiatives undertaken by the government to increase the adoption of AI-assisted technologies for cancer diagnosis is expected to boost the market growth.

Segmental Outlook

The global artificial intelligence in cancer diagnostics market is segmented on the application, type, and End user. Based on the application, the market is sub-segmented into screening & diagnosis, tumor identification and surveillance. Based on the type, the market is sub-segmented into breast cancer, prostate cancer, lung cancer, colorectal cancer, and others including cervical cancer, blood cancer, and bone cancer. Further, on the basis of end user, the market is sub-segmented into hospitals, diagnostic centers, research organization, medical institute and academics. Among the end user, the diagnostic centers sub-segment is anticipated to hold a considerable share of the market owing to the increasing government initiatives and funding in healthcare sector.

The Breast Cancer Sub-Segment is Anticipated to Hold a Considerable Share of the Global Artificial Intelligence in Cancer Diagnostics Market

Among the type, the breast cancer sub-segment is expected to hold a considerable share of the market. This growth is attributed to the growing cases of breast cancer globally. According to the World Health Organization (WHO), over 2.3 million new cases and 685,000 fatalities due to breast cancer were estimated in 2021. Additionally, around half of all breast cancers occur in women along with no specific risk factors. Thus, utilizing advanced technologies such as AI & ML in detecting breast cancer supports at early stages further contributing to the industry growth. With the detection of cancer at early stages, proper treatment can be provided to the patients, resulting in low death rates.

Regional Outlook

The global artificial intelligence in cancer diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the rising number of cancer cases around the globe. According to Canadian Cancer Statistics, 43% of women and 45% of men in Canada would have cancer in their lifetime. Nevertheless, to combat this problem, the country is actively adopting AI across the healthcare industry.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Artificial Intelligence in Cancer Diagnostics Market

The Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to an increasing adoption of AI and ML in health and several government initiatives in the region lead to an increase in investment by government as well as private organizations. Also increasing cases of cancer in the region is a driving factor for AI adoption in healthcare for early diagnostics. According to Indian Council of Medical Research-National Cancer Registry Programme (ICMR-NCRP), the government informed Parliament the number of cancer cases in the country is projected to go up from $17.7 million in 2022 to $19.0 million in 2025. For instance, NITI Aayog, the public policy think tank of the Indian Government, aims to build an Imaging Biobank in association with the Department of Biotechnology, wherein it will create a database of cancer-related pathology and radiology images of more than 20,000 profiles of patients.

Hence, there is considerable shift of the country towards the adoption of the Artificial Intelligence in Cancer Diagnostics market solutions. For instance, according to an article by the NCBI in April 2022, AI-assisted colonoscopy increased the adenoma detection rate to 29% as compared to conventional colonoscopy, which was about 20%. This is important as 1% increase in adenoma detection rate is associated with 3% decrease in colorectal cancer prevalence. AI allows the integration of a wide variety of streams such as genomics, EHR, radiographic images, pathology, and social networks to predict clinical decisions, which is expected to improve patient outcome.

Market Players Outlook

The major companies serving the artificial intelligence in cancer diagnostics market include: IBM Corp, Intel Corp, Pfizer Inc., Microsoft Corp, Janssen Pharmaceuticals, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PathAI completed the acquisition of Poplar Healthcare PLLC, an independent anatomic pathology laboratory services provider. Through this acquisition, the company would be able to integrate testing services into its existing artificial intelligence-powered pathology platform. Poplar offers specialized testing services in a range of areas, from oncology to women's health to dermatology.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global artificial intelligence in cancer diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. IBM Corp.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Microsoft Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Artificial Intelligence in Cancer Diagnostics Market by Application
    • 4.1.1. Screening & Diagnosis
    • 4.1.2. Tumor Identification
    • 4.1.3. Surveillance
  • 4.2. Global Artificial Intelligence in Cancer Diagnostics Market by Type
    • 4.2.1. Breast Cancer
    • 4.2.2. Prostate Cancer
    • 4.2.3. Lung Cancer
    • 4.2.4. Colorectal Cancer
    • 4.2.5. Others (Cervical Cancer, Blood Cancer, Bone Cancer, and Other)
  • 4.3. Global Artificial Intelligence in Cancer Diagnostics Market by End User
    • 4.3.1. Hospitals
    • 4.3.2. Diagnostic Centers
    • 4.3.3. Research Organization
    • 4.3.4. Medical Institute and Academics

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Therapixel
  • 6.2. Sophia Genetics SA
  • 6.3. Freenome Holdings, Inc.
  • 6.4. Tempus Labs, Inc.
  • 6.5. Janssen Pharmaceuticals
  • 6.6. Path AI Inc.
  • 6.7. DeepMind Technologies Ltd.
  • 6.8. Cerner Corp.
  • 6.9. RaySearch Laboratories
  • 6.10. Flatiron health
  • 6.11. Whiterabbit.ai
  • 6.12. Oncology Analytics Inc.
  • 6.13. Oncora Medical
  • 6.14. Ibex Medical Analytics Ltd.
  • 6.15. 4basecare Onco Solutions Pvt. Ltd .

LIST OF TABLES

  • 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SCREENING AND DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER TUMOR IDENTIFICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BREAST CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LUNG CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL ARTIFICIAL INTELLIGENCE IN COLORECTAL CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 10. GLOBAL ARTIFICIAL INTELLIGENCE IN OTHER TYPES OF CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS BY HOSPITALS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER MEDICAL INSTITUTE AND ACADEMICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 16. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 22. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 24. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SCREENING AND DIAGNOSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER TUMOR IDENTIFICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SURVEILLANCE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BREAST CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PROSTATE CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LUNG CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ARTIFICIAL INTELLIGENCE IN COLORECTAL CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL ARTIFICIAL INTELLIGENCE IN OTHER TYPES OF CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTICS MARKET SHARE ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER HOSPITAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER RESEARCH ORGANIZATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER MEDICAL INSTITUTE AND ACADEMICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. US ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CANADA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. UK ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. FRANCE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. GERMANY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. ITALY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. SPAIN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. INDIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. CHINA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. JAPAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)